|
Orthologous residues
|
|
Grb10 (human): Y67‑p, Grb10 (mouse): N13‑p, Grb10 (rat): ‑
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
CHO (fibroblast) [EphB1 (human), transfection]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
hamster
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Fyn (human)
|
genetic transfer of dominant-negative enzyme, transfection of constitutively active enzyme
|
|
|
KINASE
|
Src (human)
|
genetic transfer of dominant-negative enzyme, transfection of constitutively active enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
insulin
|
|
|
|
increase
|
|
|
vanadate
|
insulin
|
|
|
augment treatment-induced increase
|
|
|
herbimycin A
|
vanadate
|
|
|
inhibit treatment-induced increase
|
|
|
vanadate
|
|
|
|
no change compared to control
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
InsR (human)
|
|
Disrupts
|
|
|
co-immunoprecipitation
|
|
